Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology, Rare Disease Drugs Dominate New China Approvals

Mix Of Nods For Foreign, Local Firms

Executive Summary

Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.

You may also be interested in...



China Inc. Shines In Latest Batch Of Approvals

Chinese domestic firms have gained a flurry of novel drug approvals at home, including the first globally for an anti-PD-1 antibody for nasopharyngeal carcinoma.

China At Global Rare Disease Crossroads: CANbridge CEO

The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.

Mundipharma Set To Divest China Business?

In the latest sign that some multinationals are scaling down operations in the world's second-largest pharma market, Mundipharma is reported to be exploring the sale of its business in China, with a large group of bidders including state-owned Sinopharm and local private equity firm Boyu Capital in the running.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel